Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
